Cardiogenetics

For Genetic Tests, Size Matters 

next gen sequencing

A study in JAMA Cardiology found that broader genetic tests are better at identifying patients with cardiomyopathies and arrhythmias than disease-specific tests, despite perceived drawbacks. 

Currently, physicians typically use tests that are designed to find a specific type of cardiomyopathy or a specific type of arrhythmia. This is because examining a larger slice of a person’s genome will inherently capture a greater number of genetic mutations, and sometimes clinicians do not know what the impact of a genetic change will be on the patient’s risk. 

This uncertainty can create confusion for both the clinician and the patient. The authors of an editorial on the study explain that these “gray zone” variants are often seen as the price you pay for broader tests. 

But this retrospective study challenges that outlook. Physicians ordered combined cardiomyopathy and arrhythmia genetic testing for 4,789 patients and found that the combined testing identified clinically relevant variants for 1 in 5 patients:

  • 954 of 4,789 (20%) were flagged as a “positive” result.
  • 66% of these positives (630 patients) provided meaningful information that could inform clinical decision-making.
  • If testing had been restricted to panels associated with the clinician-provided diagnostic indications, 75 of 689 positive results (11%) would have been missed.

The Takeaway

In contrast to typical practice, it appears that more comprehensive genetic panels produce meaningful insights that could guide physician decision-making. When it comes to testing for cardiomyopathies and arrhythmias, the added burden of uncertainty may be worth it.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Cardiac Imaging June 16, 2025

Beyond Hardware: Is AI the Answer to Making Cardiac Imaging more Accessible? June 16, 2025

Sponsored by Philips Healthcare Cardiac imaging has traditionally improved through hardware advances, enabling the speed needed for high-quality images. However, hardware is rapidly reaching its physical limitations in suppressing cardiac motion and represents a large financial investment. Today, software and AI are driving the next leap in cardiac image quality and motion control – offering […]

Cardiology Pharmaceuticals June 12, 2025

FDA Approves a New BP Triple Polypill June 12, 2025

Bringing a more effective BP therapy to the U.S. market, the FDA approved George Medicines’ triple therapy polypill called Widaplik for patients with hypertension, making it the first of its kind to go to market in the U.S. Widaplik’s approval stems from two studies, including one comparing the polypill against placebo as an initial treatment […]

Cardiology Pharmaceuticals June 12, 2025

Pharmacologic Preconditioning to Improve Outcomes in Patients Undergoing Cardiac Surgery  June 12, 2025

The majority of patients undergoing cardiac surgery, especially those on cardiopulmonary bypass (CPB), experience post-operative complications such as new-onset atrial fibrillation (POAF) and acute kidney injury (AKI), largely driven by oxidative stress and inflammation.   Several approaches have been explored to reduce complications following cardiac surgery, however, a clinically meaningful impact has yet to be realized.  […]

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!